Age-related Macular Degeneration Treatment Market Size Report By 2033

The global age-related macular degeneration treatment market size reached USD 11.28 billion in 2023 and is expected to surpass around USD 22.05 billion by 2033, expanding at a CAGR of 6.93% from 2024 to 2033.

Key Points

The North America age-related macular degeneration treatment market size reached USD 5.75 billion in 2023 and is expected to expand around USD 11.36 billion by 2033, at a CAGR of 7.04% from 2024 to 2033.
North America led the market with the largest revenue share of 51% in 2023.
Asia-Pacific is expected to experience the fastest rate of growth during the forecast period.
By product, the eylea segment has held a major revenue share of 52% in 2023.
By product, the Beovu segment is expected to grow with the highest CAGR during the forecast period.
By disease type, the wet AMD segment has contributed more than 98% of revenue share in 2023.
By disease type, the dry AMD segment is expected to be the fastest-growing segment during the forecast period.
By distribution channel, the hospital pharmacy segment has held a biggest revenue share of 52% in 2023.
By distribution channel, the specialty pharmacy segment is estimated to witness the fastest growth during the forecast period.

Age-related Macular Degeneration Treatment Market Size 2024 to 2033

Age-related macular degeneration (AMD) is a progressive eye condition that affects the macula, the central part of the retina responsible for sharp, central vision. It primarily occurs in individuals over the age of 50 and can lead to severe vision impairment or blindness if left untreated. The market for AMD treatment encompasses various therapeutic approaches aimed at slowing down disease progression and preserving vision. These treatments range from pharmacological interventions to surgical procedures, each targeting different stages and forms of AMD.

Get a Sample: https://www.precedenceresearch.com/sample/4462

Table of Contents

Growth Factors

The AMD treatment market is driven by several key factors contributing to its growth. First and foremost is the aging global population, particularly in developed countries where the prevalence of AMD is higher. As life expectancy increases, so does the incidence of AMD, creating a larger patient pool requiring treatment. Additionally, advancements in diagnostic techniques and early detection have improved the identification of AMD cases, leading to earlier intervention and treatment initiation. Furthermore, ongoing research and development efforts in biotechnology and pharmaceutical sectors continue to innovate new therapies and improve existing treatment options, driving market growth.

Trends

Several trends are shaping the landscape of AMD treatment. One prominent trend is the shift towards biologic therapies and targeted pharmacological agents. These treatments aim to address specific mechanisms of AMD pathology, such as anti-vascular endothelial growth factor (VEGF) therapies that target abnormal blood vessel growth in the retina. Another trend is the development of combination therapies that offer synergistic effects in managing AMD progression. Additionally, advancements in drug delivery systems, including sustained-release implants and intravitreal injections, are enhancing treatment efficacy and patient compliance.

Region Insights

The prevalence and treatment patterns of AMD vary significantly across regions. Developed countries, such as the United States, Europe, and Japan, exhibit higher rates of AMD due to aging populations and better healthcare infrastructure for diagnosis and treatment. These regions also lead in terms of research and development expenditure, fostering innovation in AMD therapies. In contrast, emerging economies in Asia-Pacific, Latin America, and Africa are witnessing a rising prevalence of AMD due to demographic shifts and improving access to healthcare. However, challenges such as affordability and access to advanced treatments remain significant barriers in these regions.

Age-related Macular Degeneration Treatment Market Scope

Report Coverage	Details
Market Size in 2023	USD 11.28 Billion
Market Size in 2024	USD 12.06 Billion
Market Size by 2033	USD 22.05 Billion
Market Growth Rate	CAGR of 6.93% from 2024 to 2033
Largest Market	North America
Base Year	2023
Forecast Period	2024 to 2033
Segments Covered	Product, Disease Type, Distribution Channel, and Regions
Regions Covered	North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa

Age-related Macular Degeneration Treatment Market Dynamics

Drivers

Several drivers propel the growth of the AMD treatment market. One of the primary drivers is the increasing awareness and proactive screening initiatives among healthcare providers and patients, leading to early diagnosis and treatment. Additionally, the growing acceptance and adoption of novel therapies by ophthalmologists and retina specialists contribute to market expansion. Moreover, supportive regulatory frameworks and reimbursement policies in key markets facilitate market penetration for innovative AMD treatments, driving demand and uptake.

Opportunities

The AMD treatment market presents several opportunities for stakeholders. Expanding market access in emerging economies represents a significant opportunity for pharmaceutical companies and medical device manufacturers to tap into a growing patient pool. Moreover, collaborations between academia, industry, and healthcare providers can accelerate research and development efforts, leading to the discovery of breakthrough therapies. Furthermore, leveraging digital health technologies and telemedicine solutions can enhance patient engagement and adherence to treatment regimens, thereby improving outcomes in AMD management.

Challenges

Despite its growth prospects, the AMD treatment market faces several challenges. One major challenge is the high cost associated with innovative therapies, which may limit access for patients, particularly in developing countries or underinsured populations. Additionally, the complexity of AMD pathophysiology presents challenges in developing universally effective treatments that address all forms and stages of the disease. Furthermore, regulatory hurdles and stringent approval processes for new treatments can prolong time-to-market and increase development costs, impacting market dynamics.

Age-related Macular Degeneration Treatment Market Companies

F. Hoffmann-La Roche Ltd.
Novartis AG
Pfizer Inc.
Bausch Health Companies Inc.
Regeneron Pharmaceuticals Inc.
Amgen Inc.
Bayer AG
Biogen
Samsung Bioepis
Abbvie, Inc

Recent Developments

In October 2023, Genentech announced that the U.S. Food and Drug Administration (FDA) had approved Vabysmo for the treatment of Retinal Vein Occlusion (RVO), neovascular or wet age-related macular degeneration, and diabetic macular edema.
In August 2023, Regeneron Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) had approved EYLEA HD injection for treating patients suffering from wet age-related macular degeneration.
In August 2023, Astellas Pharma Inc. announced that the U.S. Food and Drug Administration (FDA) had approved IZERVAY injection for geographic atrophy (GA) and age-related macular degeneration (AMD) disease.
In February 2023, Apellis announced that the U.S. Food and Drug Administration (FDA) had approved SYFOVRE injection for the treatment of geographic atrophy (GA) and age-related macular degeneration (AMD) disease.

Segments Covered in the Report

By Product